Core Viewpoint - Hengdian East Magnetic achieved a net profit attributable to shareholders of 1.02 billion yuan in H1 2025, representing a year-on-year increase of 58.94% [1] - The company’s Q2 2025 net profit reached 562 million yuan, with a remarkable year-on-year growth of 94.80% [1] Group 1: Financial Performance - The company’s strategic focus is on strengthening its magnetic materials business and developing new energy [1] - The magnetic materials segment is experiencing steady growth, while new products like copper sheet inductors are expected to create new growth points [1] - Despite the backdrop of overcapacity in the photovoltaic sector, the company maintains high growth in shipment volume and continuous improvement in profitability [1] Group 2: Market Outlook - Due to the impact of U.S. tariffs on the company’s production capacity in Indonesia, the profit forecasts for 2025 and 2026 have been slightly adjusted downwards [1] - The projected net profits attributable to shareholders for 2025, 2026, and 2027 are 2.0 billion, 2.29 billion, and 2.55 billion yuan respectively, with corresponding price-to-earnings ratios of 16.9, 14.8, and 13.2 times [1] - The company maintains a "buy" rating despite the adjustments in profit forecasts [1]

固定收益 | 固定收益专题 利率专题 证券研究报告 国债新老券利差如何演绎？ 愈发难以博弈的国债新老券利差 理论上讲，新老券利差应为正值，且在上市初期、切券之后两个时间段出 现利差走阔，切券后一段时间利差达到峰值，随后回落至趋向于零。实际 来看规律逐渐"失效"。具体来看 10Y 和 30Y 国债的新老券利差表现： 1）上市与切券之后，新老券利差最大走阔幅度统计 平均来看，10Y（30Y）国债在上市后的 13（11）个交易日达到第一个利差 峰值，新老券利差最大走阔 1.85BP(1.27BP)；在上市后的 22(30)个交易日成 为活跃券，切券后 44(58)个交易日达到第二个利差峰值，新老券利差最大 走阔 3.07BP(4.31BP)。 不过，从最近的切券经验来看，对于有潜力成为活跃券的新券，市场会快 速参与并加快切券节奏，新老券利差的策略空间被压缩。例如，10Y 国债 250011 上市次日即完成切券，切券之后，新老券利差最大走阔幅度仅 0.45BP。30Y 特别国债 2500002 在上市的 8 个交易日后也顺利成为活跃券。 切券之后，新老券利差最大走阔幅度仅 2.95BP，也处于历史中等偏低水平。 新老 ...

Core Viewpoint - The current glass varieties are below the 50th percentile of the past three years, while cement is above glass, indicating a potential for recovery in undervalued glass products [1] Industry Analysis - The Ministry of Industry and Information Technology, along with five other departments, released the "Construction Materials Industry Stabilization and Growth Work Plan (2025-2026)" to address weak market demand and structural issues in the construction materials sector [1] - The plan outlines the main goals and initiatives for the industry in 2025-2026, aiming to improve the competitive landscape through accelerated capacity reduction [1] Company Insights - Companies such as China National Building Material, Conch Cement, and Jinju Group are performing around the 80th percentile of the past three years, while China Resources Cement Technology is relatively lower [1] - Western Cement and Huaxin Cement are performing relatively higher, suggesting varying levels of market strength among these companies [1] - The low valuation of glass products is expected to provide greater elasticity for recovery, making them attractive investment opportunities [1]

Core Viewpoint - The construction materials industry showed signs of recovery in H1 2025, with a total revenue of 270.9 billion yuan, a year-on-year decline of 5.9%, but a significant improvement in net profit, which reached 14.3 billion yuan, up 23.9% year-on-year, indicating a potential bottoming out of the real estate market supported by government policies [1][2]. Revenue and Profit Analysis - In H1 2025, the construction materials sector generated total revenue of 270.9 billion yuan, reflecting a year-on-year decrease of 5.9%, with Q2 showing a similar decline compared to Q1 [2]. - The net profit attributable to shareholders in H1 2025 was 14.3 billion yuan, representing a year-on-year increase of 23.9%, with Q2 net profit growing by 30.2% year-on-year, an acceleration from Q1 [1][2]. Subsector Performance - **Cement**: In H1 2025, cement revenue was 118.1 billion yuan, down 7.7% year-on-year, but net profit surged by 1487% to 5.2 billion yuan, benefiting from price and cost improvements. The sector is expected to show a gradual improvement in the second half of the year due to supply-side restrictions and demand from infrastructure projects [3]. - **Consumer Building Materials**: This segment generated revenue of 66.9 billion yuan, down 3.8% year-on-year, with net profit declining by 12.8% to 4.4 billion yuan. The performance varied across subcategories, with paint showing a profit increase while other categories like tiles and pipes faced significant declines [4]. - **Glass Fiber**: The glass fiber sector reported a revenue increase of 20.8% to 5.2 billion yuan and a net profit increase of 127% to 1.1 billion yuan, driven by significant price recovery [5]. Investment Recommendations - The report suggests focusing on companies with strong competitive advantages in the construction materials sector, particularly those in cement and glass fiber, as well as leading firms in consumer building materials like Sanke Tree and Beixin Building Materials, which are expected to benefit from a stabilizing real estate market [4][5].

Group 1 - The core viewpoint is that the market is expected to gradually trend upwards, indicating a slow bull market supported by various factors [1][2] - The "anti-involution" trend this year emphasizes high-quality development and a focus on technology rather than price wars [1][2] - The market has shown a gradual improvement in profitability, with strong performance in certain industries and the discovery of value sectors [1] Group 2 - From a technical and capital perspective, the market appears robust, with wealth transfer among residents indicating stability [1] - Policy support is facilitating industry consolidation through mergers and acquisitions, allowing excellent companies to receive more funding [1][2] - The best performers in the past year have been leading companies, which have benefited from favorable capital market policies, enhancing their premium and driving industry growth [1] Group 3 - The capital market's role in servicing and activating the real economy is being emphasized, with strong policy support for market development [2] - Despite the ongoing impact of real estate on the economy, artificial intelligence is progressively driving structural improvements across various sectors [2] - A+H listings are on the rise, reflecting the country's openness to international capital and enhancing the international image of the capital market [2]

Group 1 - The core viewpoint is that the market is expected to gradually trend upwards, indicating a slow bull market supported by various factors, including a focus on high-quality development and technology rather than price wars [1][2] - The current market performance reflects a strong technical and capital foundation, with wealth transfer among residents contributing to market stability [1] - Policy support is facilitating industry consolidation through mergers and acquisitions, allowing excellent companies to receive more funding and better market pricing [1][2] Group 2 - The analysis of future market trends includes considerations of the fundamental, policy, technical, and capital aspects, with a focus on the positive impact of artificial intelligence across various sectors [2] - The A+H listing trend since 2025 represents China's economic openness to international capital, helping outstanding companies secure better funding and showcasing the internationalization of the capital market [2] - The concept of "anti-involution" has emerged as a key term in the Chinese economy since 2025, promoting a shift towards high-quality development and technology-centric approaches [2]

Core Viewpoint - Junshi Bioscience reported a significant revenue increase and reduced net loss in H1 2025, driven by the performance of its flagship drug, Toripalimab, which is gaining traction in the domestic market with new indications approved [1] Financial Performance - In H1 2025, Junshi Bioscience's revenue reached 1.168 billion yuan, marking a year-on-year growth of 48.64% [1] - The net loss for the same period was 413 million yuan, reflecting a year-on-year reduction in loss by 36.01% [1] Product Development and Approvals - Toripalimab's domestic sales revenue was approximately 954 million yuan in H1 2025, representing a year-on-year increase of about 42% [1] - The drug has received approval for a total of 12 indications in China, with two new indications added in 2025, including liver cancer and melanoma [1] - A supplemental new drug application (sNDA) for the combination treatment of HER2+ urothelial carcinoma has been accepted by NMPA [1] Clinical Trials and Research - The PD-1/VEGF dual antibody JS207 is currently in Phase II clinical trials, showing strong anti-tumor activity in preclinical studies [1] - The drug is being explored in combination therapies across various cancer types, including NSCLC, CRC, TNBC, and liver cancer [1] - The international clinical trial for BTLA in LS-SCLC has enrolled nearly 400 participants [1] International Expansion - Junshi Bioscience has established commercial partnerships in over 80 countries, including the EU and the UK, with approvals in 40 regions such as the US, EU, UK, and Australia [1] - The company achieved commercialization in the US and received approval for nasopharyngeal cancer treatment in Australia in January 2025 [1] Investment Rating - The company maintains a "Buy" rating based on its robust pipeline and market performance [1]

Core Insights - Qianhong Pharmaceutical achieved a revenue of 862 million yuan in H1 2025, representing a year-on-year increase of 0.72% [1] - The company reported a net profit attributable to shareholders of 258 million yuan, reflecting a year-on-year growth of 41.17% [1] - The revenue from the formulation segment was 543 million yuan, showing a decline of 7.15% year-on-year, while the gross margin for this segment improved to 69.90%, an increase of 8.54 percentage points year-on-year [1] Clinical Development - As of June 30, 2025, the company has four innovative drugs in phase II clinical trials or about to enter phase III, with several others in phase I or awaiting approval for clinical research [1] - The original Class I new drug QHRD107 capsule has completed phase IIa clinical trials and has been successfully published at the EHA annual meeting, currently applying to the CDE for phase IIb clinical research [1] - The original Class I new drug QHRD106 injection has completed phase II clinical trials and is currently applying to the CDE for phase III clinical research [1] Financial Forecast - Based on the stable revenue growth and rapid profit increase in H1 2025, the revenue forecasts for 2025-2027 have been updated to 1.749 billion yuan, 2.091 billion yuan, and 2.500 billion yuan respectively [1] - The net profit forecasts for 2025-2027 have been updated to 459 million yuan, 423 million yuan, and 475 million yuan respectively [1] - The company maintains an "overweight" rating [1]

Core Viewpoint - Yuheng Pharmaceutical achieved a net profit attributable to shareholders of 134 million yuan in H1 2025, representing a year-on-year increase of 7.56% [1] Financial Performance - The company's asset-liability ratio decreased from 31.66% in the same period last year to 28.70%, indicating an ongoing optimization of the asset-liability structure and enhanced risk resistance [1] Strategic Partnerships - In H1 2025, the company signed a joint promotion agreement for Pemafibrate tablets with Xinghe Pharmaceutical and a market promotion service agreement for Mecobalamin injection with Eisai (China) [1] - Pemafibrate tablets, as a new generation of fibrate drugs, have broad market prospects, which will enrich the company's product pipeline and potentially increase revenue and profit [1] Competitive Positioning - The promotion of Pemafibrate tablets is expected to enhance the company's competitiveness in the cardiovascular field and improve its specialized academic promotion capabilities, laying the foundation for future product collaborations [1] Investment Rating - The company maintains a "Buy" rating [1]

"总体上看，未来一段时间央行会综合运用买断式逆回购、MLF两项政策工具，持续向市场注入中期流 动性。"王青认为，这在助力政府债券发行，引导金融机构加大货币信贷投放力度的同时，也将释放数 量型政策工具持续加力信号，显示货币政策延续支持性立场。 央行货币政策委员会第三季度例会提到，建议加强货币政策调控，提高前瞻性、针对性、有效性，根据 国内外经济金融形势和金融市场运行情况，把握好政策实施的力度和节奏，抓好各项货币政策措施执 行，充分释放政策效应。保持流动性充裕，引导金融机构加大货币信贷投放力度，使社会融资规模、货 币供应量增长同经济增长、价格总水平预期目标相匹配。 目前，央行基础货币投放的渠道已较为丰富。市场人士预计，央行将通过质押式逆回购维持短期流动性 平衡，MLF和买断式逆回购提供中期流动性，降准叠加恢复国债买卖向市场注入长期流动性，以保持 市场流动性合理充裕。 10月9日，央行以固定数量、利率招标、多重价位中标方式开展1.1万亿元买断式逆回购操作，期限为3 个月（91天），加量续作3000亿元。 "十一"长假后，银行间市场资金回笼压力明显加大。10月9日至10日，公开市场逆回购到期量分别为 20633亿元和 ...